IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
Details of the oral presentation are as follows:
Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression
Session Type: In-Person Oral Presentation
Session Title: Novel Production Platforms
Abstract Number: 282
Location: Ballroom 2
Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm ET
Abstracts are available at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024. A copy of the presentation will be available at https://in8bio.com once the presentation concludes.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Corporate Contact:
IN8bio, Inc.
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com
Investors
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
紐約,2024 年 4 月 24 日(GLOBE NEWSWIRE)— in8Bio, Inc. 納斯達克股票代碼:INAB)是一家開發創新伽瑪-德爾塔T細胞療法的臨床階段生物製藥公司,今天宣佈在2024年5月7日至11日在馬里蘭州巴爾的摩舉行的美國基因與細胞療法學會(ASGCT)2024年年會上進行口頭演講。
Details of the oral presentation are as follows:
口頭陳述的詳情如下:
Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression
標題:健康捐贈者與患者製造的自體 Deltex DRI 產品;免疫表型基因表達
Session Type: In-Person Oral Presentation
會議類型:面對面的口頭陳述
Session Title: Novel Production Platforms
會議標題:小說製作平台
Abstract Number: 282
摘要編號:282
Location: Ballroom 2
地點:2 號宴會廳
Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm ET
演講日期/時間:美國東部時間5月10日星期五下午 3:45 — 4:00
Abstracts are available at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024. A copy of the presentation will be available at https://in8bio.com once the presentation concludes.
摘要可在以下網址獲得:https://annualmeeting.asgct.org/。這些數據將在發佈日(2024年5月10日星期三)美國東部時間上午6點之前禁運。演示文稿的副本將在以下網址獲得 https://in8bio.com 演示結束後。
About IN8bio
關於 in8Bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
in8bio是一家臨床階段的生物製藥公司,爲癌症患者開發基於伽瑪-德爾塔T細胞的免疫療法。gamma-delta T 細胞是一組特殊的 T 細胞,具有獨特的特性,包括區分健康組織和病變組織的能力。該公司的牽頭項目 INB-400 正在進行多形性膠質母細胞瘤(GBM)的二期試驗。其他項目包括實體腫瘤和血液學腫瘤的 1 期試驗,包括針對 GBM 的 INB-200 和針對接受移植的血液系統惡性腫瘤患者的 INB-100。有關in8bio的更多信息,請訪問www.in8bio.com。
Corporate Contact:
IN8bio, Inc.
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com
公司聯繫人:
in8Bio, Inc.
格倫·舒爾曼,藥學博士,公共衛生碩士
203.494.7411
gdschulman@IN8bio.com
Investors
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
投資者
梅魯顧問
李 M. 斯特恩
lstern@meruadvisors.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
媒體聯繫人
金伯利哈
KKH 顧問
917.291.5744
kimberly.ha@kkhadvisors.com
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧